| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04759833 2022-003221-22 Details | 2024-01-18 Interventional | 3 | 175 | Prucalopride Constipation | Data Monitoring Committe (DMC) decision; terminated due to futility, with no safety concerns;
FDA agreement to terminate the study. - | |||
| NCT04539366 Details | 2024-01-18 Interventional | 1 | - | Cyclophosphamid… Fludarabine Fludarabine pho… Neuroblastoma Osteosarcoma Recurrence Recurrent Neuro… Recurrent Osteo… Refractory Neur… Refractory Oste… | Interim Monitoring - | |||
| NCT03128034 Details | 2024-01-18 Interventional | 1/2 | - | Cyclosporine Cyclosporins Fludarabine Fludarabine pho… Mycophenolic Ac… Acute Disease Anemia, Refract… Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Precursor Cell … Preleukemia Recurrence Syndrome Acute Lymphobla… Acute Myeloid L… Acute Myeloid L… Chronic Myelomo… Mixed Phenotype… Myelodysplastic… Recurrent Acute… Recurrent Acute… Recurrent Mixed… Refractory Acut… Refractory Acut… Refractory Mixe… | Administrative - FDA Comments - | |||
| NCT02829723 2015-005806-12 Details | 2024-01-18 Interventional | 1/2 | 192 | Spartalizumab Neoplasms Advanced Solid … | - - | |||
| NCT02031419 Details | 2024-01-18 Interventional | 1 | 174 | Rituximab Spebrutinib Lymphoma Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Large… | Replaced with another clinical trial. - | |||
| NCT04398316 Details | 2024-01-17 Interventional | 4 | 4 | Hydromorphone Lidocaine Abdominal Pain Emergencies Renal Colic | Administrative No statistical analysis was done due to enrolling only 4 subjects before the trial was terminated. | |||
| NCT01898793 Details | 2024-01-17 Interventional | 1/2 | 89 | Aldesleukin Cyclophosphamid… Fludarabine Fludarabine pho… Interleukin-2 Leukemia Leukemia, Myelo… Leukemia, Myelo… | Insufficient funding/staff - | |||
| NCT04785547 Details | 2024-01-16 Interventional | 2 | 3 | Blinatumomab Neoplasm, Resid… Precursor Cell … ALL, Childhood Minimal Residua… | Terminated by Amgen Limited - | |||
| NCT04261439 2019-004069-42 Details | 2024-01-16 Interventional | 1 | 60 | Spartalizumab Tislelizumab Lymphoma Melanoma In Escalation: … In Expansion: M… | Business decision and not due to any safety concerns - | |||
| NCT03992131 2018-003759-39 Details | 2024-01-16 Interventional | 1/2 | 25 | Rucaparib Sacituzumab gov… Triple Negative… Ovarian Cancer Solid Tumor Triple-negative… Urothelial Carc… | Due to a change in development priorities, no further clinical development of the lucitanib
plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time. The study was terminated due to Sponsor's decision to discontinue development of the combination of rucaparib and sacituzumab govitecan. | |||
| NCT03840902 2018-003265-34 Details | 2024-01-16 Interventional | 2 | 153 | Carboplatin Durvalumab Etoposide Paclitaxel Pemetrexed Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Based on recommendations by an external Independent data Monitoring Committee (IDMC), Sponsor
decided to discontinue this clinical study due to a low likelihood of achieving superiority in
the efficacy endpoints versus standard of care. - | |||
| NCT03729401 Details | 2024-01-16 Interventional | 4 | - | Aspirin Clopidogrel Ticagrelor Coronary Artery… Infarction Myocardial Infa… | Testing supplies unavailable. - | |||
| NCT04864782 Details | 2024-01-12 Interventional | 2/3 | 46 | Carboplatin Paclitaxel Uterine Cervica… Cervical Cancer | Phase 2 completed, phase 3 sponsor decided to terminate - | |||
| NCT04842331 Details | 2024-01-12 Interventional | 2/3 | 0 | Nitric Oxide COVID-19 Communicable Di… Infections Respiratory Tra… Respiratory Tra… Virus Diseases COVID-19 Respir… Respiratory Vir… | A combination of factors, including the dynamic nature of the COVID-19 pandemic and the
successful vaccination program, has resulted in a very sharp decline in the number of patients
with COVID-19 - | |||
| NCT04243837 Details | 2024-01-12 Interventional | 1/2 | 50 | Pirfenidone Breast Cancer L… Breast Neoplasm… Lymphedema Breast Cancer R… Lymphoedema | Primary objective/endpoint has been established, will not pursue development of the disease
indication further - | |||
| NCT03847272 Details | 2024-01-12 Interventional | 2 | 15 | Prednisone Ustekinumab Uveitis Patients With N… | The long inclusion period meant that the question could not be answered within an appropriate
timeframe. - | |||
| NCT03346083 2018-002562-40 Details | 2024-01-12 Interventional | 1 | 21 | Betrixaban VTE Prophylaxis | After completion of Part 1 and prior to initiating Part 2, the Sponsor decided to cease
developing betrixaban, prompting early study closure. After completion of Part 1 and prior to initiating Part 2, the Sponsor decided to cease developing betrixaban, prompting early study closure. | |||
| NCT05445128 Details | 2024-01-11 Interventional | 2 | 1 | Plerixafor Anemia, Sickle … Sickle Cell Dis… | This study was voluntarily terminated due to a business decision not to proceed, and not due to
any safety issue. - | |||
| NCT04918147 Details | 2024-01-11 Interventional | 2 | 8 | Acetaminophen Diphenhydramine Elotuzumab Famotidine Methylprednisol… Methylprednisol… Prednisone Promethazine Immunoglobulin … IgG4 Related Di… IgG4-RD | The study was terminated early based on disease flare/lack of efficacy in the early phase of
the trial. - | |||
| NCT01774487 Details | 2024-01-11 Interventional | 2 | 17 | Pentoxifylline Biliary Atresia | Target enrollment was not reached because the medication, pentoxifylline, has a taste that is
not well tolerated by infants. The study team decided to end the study before meeting the
enrollment goal because of the medication taste. Because of early termination, this study did not reach the target number of participants needed to achieve target power and statistically reliable results. |